Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?

ABSTRACT:

Objectives/hypothesis

To examine whether there is a rationale for iron treatments precipitating nosebleeds (epistaxis) in a subgroup of patients with hereditary hemorrhagic telangiectasia (HHT).

Study design

Survey evaluation of HHT patients, and a randomized control trial in healthy volunteers.

Methods

Nosebleed severity in response to iron treatments and standard investigations were evaluated by unbiased surveys in patients with HHT. Serial blood samples from a randomized controlled trial of 18 healthy volunteers were used to examine responses to a single iron tablet (ferrous sulfate, 200 mg).

Results

Iron tablet users were more likely to have daily nosebleeds than non-iron-users as adults, but there was no difference in the proportions reporting childhood or

SUBMITTER: Shovlin CL 

PROVIDER: S-EPMC5095791 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature